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ABSTRACT
TGF-β1 is a major player in chronic liver diseases promoting fibrogenesis and 
tumorigenesis through various mechanisms. The expression and function of TGF-β2 
have not been investigated thoroughly in liver disease to date. In this paper, we 
provide evidence that TGF-β2 expression correlates with fibrogenesis and liver cancer 
development. 
Using quantitative realtime PCR and ELISA, we show that TGF-β2 mRNA 
expression and secretion increased in murine HSCs and hepatocytes over time in 
culture and were found in the human-derived HSC cell line LX-2. TGF-β2 stimulation of 
the LX-2 cells led to upregulation of the TGF-β receptors 1, 2, and 3, whereas TGF-β1 
treatment did not alter or decrease their expression. In liver regeneration and fibrosis 
upon CCl4 challenge, the transient increase of TGF-β2 expression was accompanied 
by TGF-β1 and collagen expression. In bile duct ligation-induced fibrosis, TGF-β2 
upregulation correlated with fibrotic markers and was more prominent than TGF-β1 
expression. Accordingly, MDR2-KO mice showed significant TGF-β2 upregulation 
within 3 to 15 months but minor TGF-β1 expression changes. In 5 of 8 hepatocellular 
carcinoma (HCC)/hepatoblastoma cell lines, relatively high TGF-β2 expression and 
secretion were observed, with some cell lines even secreting more TGF-β2 than 
TGF-β1. TGF-β2 was also upregulated in tumors of TGFα/cMyc and DEN-treated mice. 
The analysis of publically available microarray data of 13 human HCC collectives 
revealed considerable upregulation of TGF-β2 as compared to normal liver. 
Our study demonstrates upregulation of TGF-β2 in liver disease and suggests 
TGF-β2 as a promising therapeutic target for tackling fibrosis and HCC.
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INTRODUCTION
Currently, liver transplantation is the only 
therapeutic option to fight terminal liver failure. The 
demand for new therapies increases due to the lack of 
donor organs and enormous economic costs, leading to a 
major medical problem. In chronic liver disease (CLD), 
tissue remodeling and wound healing are interrupted, 
resulting in complex modulation of signaling processes at 
the cellular and molecular level. Subsequent fibrosis is the 
onset of hepatic disease development including cirrhosis, 
HCC, or hepatic failure [1]. 
TGF-β is a homodimer that exists in three 
different isoforms (TGF-β1, TGF-β2 and TGF-β3) 
in mammals. All TGF-β precursor forms are secreted 
as latent homodimeric complexes, incorporated into 
the ECM, and activated by proteolytic cleavage [2]. 
Generally, the β1 and β2 isoforms are closely related and 
display about 70% amino acid sequence identity [3, 4]. 
All TGF-β ligands signal through the same receptor 
signaling systems [5], initiating various downstream 
signaling pathways [6]. The TGF-β receptors type I, 
II and III (TGFβR-I, TGFβR-II, and TGFβR-III) 
are expressed in almost every mammalian cell type, 
including cancer cells [7]. TGFβR-I and -II are essential 
for provoking the biological response of TGF-β isoforms 
[8], but can bind TGF-β3 and TGF-β1 with higher 
affinity than TGF-β2 [9–11]. TGFβRs-III (Betaglycan 
and Endoglin) are described to stabilize TGF-βs in a 
conformation that is optimal for binding to the signaling 
receptors. Betaglycan binds all TGF-β isoforms with 
high affinity [9, 10, 12] and significantly enhances the 
binding efficacy of TGF-β2 to TGFβR-II (reviewed in 
Massagué [13]). In contrast, Endoglin only binds TGF-β1 
and TGF-β3, but not TGF-β2 [14].
The three isoforms have partly overlapping but 
non-redundant functions and act as potent regulators of 
cell growth, differentiation and migration. About 60% of 
mice lacking TGF-β1 already die in utero due to deficient 
endothelial cell differentiation, which underlines its 
function in embryogenesis [15]. Surviving mice develop 
severe multi-organ inflammatory responses in the heart, 
liver, pancreas, and other organs, and show increased 
numbers of mitochondria in the liver in response to stress 
[16, 17]. Mainly developmental defects have also been 
detected in mice lacking TGF-β2, affecting epithelial-
mesenchymal interactions, cell growth, extracellular 
matrix production and tissue remodeling. TGF-β3 
knockout mice also exhibit epithelial-mesenchymal 
interaction perturbances, evidenced in mice by abnormal 
lung development and cleft palate [18].
TGF-β1 plays a pivotal role in the development 
of tissue fibrosis where it stimulates the synthesis 
and accumulation of ECM components and reduces 
their degradation by matrix metalloproteinases [19]. 
In vitro, TGF-β2 and TGF-β3 have been reported to exert 
profibrotic effects in fibrosis-related cell types [20, 21] 
such as fibroblasts. Accordingly, TGF-β2 has been 
described to be involved in the activation of mesenchymal 
cells and matrix production in fibrotic livers [22]. 
In cancer, TGF-β has a bidirectional role: It is 
involved in the promotion and inhibition of cancer 
progression mainly depending on the tumor stage 
[23, 24], with TGF-β1 being the most widely investigated 
isoform in many human cancers [25]. Less is known 
about TGF-β2, which was first described to suppress 
the effects of interleukin dependent T-cell growth [26]. 
It is released by tumors of several origins including 
glioblastomas, breast cancer, melanoma, and others [27]. 
Immunosuppression induced by TGF-β2 is assumed to be 
a main mechanism by which tumor cells can escape from 
immune surveillance. 
In the liver, all three isoforms are present, but they 
are not expressed homogeneously in all different cell types 
[28]. While TGF-β1 expression is often increased in liver 
cancer, suggesting a tumor-promoting effect [29, 30], 
little is known about TGF-β2 in this setting. One group 
has described high stromal expression of TGF-β2 in 
intrahepatic cholangiocarcinomas (ICC), which was 
accompanied by poor prognosis [31, 32, 33]. Other 
preliminary studies including only a few specimen 
describe all three isoforms as being overexpressed in HCC 
and proliferating bile ducts of fibrotic livers compared 
to normal liver [29, 34]. Moreover, overexpression of 
TGF-β2 and TGF-β3 but not TGF-β1 was found in 
cholangiocarcinoma [35]. Thus, with research mainly 
focusing on TGF-β1, to date only a few studies deal with 
the expression and function of TGF-β2 [36]. 
In this report, we comparatively analyzed TGF-β2 
and TGF-β1 expression and secretion in murine and 
human hepatic stellate cells (HSCs), hepatocytes and 
HCC/hepatoblastoma cell lines. We also investigated 
the dynamics of TGF-β1 and -β2 isoform expression in 
liver disease progression using several mouse models of 
different stages of liver disease, as well as expression in 
human HCC sample cohorts. We demonstrate that both 
isoforms are expressed in different liver cell types and 
their expression is elevated during progression of CLD 
in mouse models. Although TGF-β2 is mostly secreted at 
lower levels than TGF-β1, its expression patterns largely 
follow similar profiles. However, the secretion of TGF-β2 
exceeded that of TGF-β1 in some HCC cell lines. Our 
data further indicate a more prominent role of TGF-β2 in 
biliary-derived liver disease models. Finally, we delineated 
overexpression of TGF-β2 in human HCC patient cohorts. 
In conclusion, our data suggests that TGF-β2 probably 
plays a role in the process of CLD. Targeting TGF-β1 as 
a therapeutic approach still remains challenging and our 
findings now provide the encouragement to study TGF-β2 
as an alternative promising target for the treatment of liver 
fibrosis and HCC.
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RESULTS
Expression of TGF-β1 and TGF-β2 in murine 
hepatocytes and HSCs
TGF-β1 and TGF-β2 mRNA expression was first 
determined in mouse hepatocytes by qPCR (Figure 1A). 
Hepatocytes were isolated from C57BL/6 wild type mice 
and cultured either on collagen monolayer (CM) to mimic 
deteriorating differentiated functions and non-polarized 
structure, or on collagen sandwich (CS), representing 
re-established hepatic polarity and stable differentiated 
functions [37]. In both settings, TGF-β1 and -β2 were 
increasingly expressed with culture duration after 24 and 
48 hours. Induction was higher in CS than in CM for both 
cytokines. Although secreted at lower levels, the induction 
of TGF-β2 secretion after 48 h on CM was much stronger 
than that of TGF-β1 (Figure 1B). The discrepancy 
between the significant mRNA expression induction 
of both cytokines and the rather moderate induction of 
secretion over time suggests storage or intracrine usage 
of newly synthesized TGF-β in the cells [38] and requires 
further research.
It is well accepted that upon liver damage HSCs 
do express and secrete TGF-β1, thus inducing paracrine 
activation of quiescent HSCs, hepatocyte cytostasis in 
early stages and tumor-promoting effects in later stages 
of CLD. Here, we compared TGF-β2 mRNA expression 
and secretion in quiescent (2 days) and activated (8 days) 
primary murine HSCs. TGF-β2 mRNA expression, similar 
to TGF-β1, was increased within 8 days during HSC 
culture activation (Figure 1C). Furthermore, the secretion 
of both TGF-β isoforms was demonstrated after 2 days and 
was increased after 8 days (both ~10-fold). However, while 
only about 850 pg/ml TGF-β2 were secreted after 8 days, 
around 16,000 pg/ml TGF-β1 were detected at that time 
point (Figure 1D). ELISAs of cell lysates revealed that this 
divergence correspondend to different levels of protein in 
the cells. TGF-β1 content was stable after 2 and 8 culture 
days, but markedly higher than that of TGF-β2 (day 2 
~200-fold, day 8 ~10-fold), while intracellular TGF-β2 
levels increased about 10-fold between 2 and 8 days 
(Figure 1E). We conclude from these data the existence 
of a cytokine specific maximal limit in the cells, which 
is reached for TGF-β1 already on day 2. Additionally 
produced cytokines were secreted continuously. Thus, 
8-10-fold levels of both cytokines were found in the 
supernatant as compared to the cell lysates on day 8.
To translate our results to human HSCs and examine 
TGF-β1 and -β2 signaling in more detail, we next 
examined the human HSC cell line LX-2 with respect to 
TGF-β1 and -β2 expression. We found that both TGF-β1 
and -β2 mRNA were expressed in LX-2 cells (Figure 2A). 
As expected in a cell line, TGF-β mRNA expression was 
stable when comparing 2 days and 4 days of culture. 
Secretion of TGF-β1 after 4 days was found to be about 
1.5-fold higher than that of TGF-β2 (Figure 2B). 
We then analyzed whether TGF-β1 or TGF-β2 
secretion impacts on TGF-β signaling in HSCs. As it is 
known that TGF-β1 can influence the expression of its 
signaling receptors [39], we analyzed TGF-β receptor 
expression in LX-2 cells treated with 10 ng/ml TGF-β2 in 
comparison to TGF-β1. Although LX-2 cells are known 
to be responsive to TGF-β1, e.g. displaying strong (1α) 
procollagen upregulation [40], TGF-β1 stimulation of LX-2 
cells for 1 h or 24 h either decreased or did not alter TGF-β 
receptor expression compared to the basal expression levels 
(Figure 2C, dotted lines). In contrast, TGF-β2 stimulation 
decreased receptor expression after 1 h, but notably induced 
TGF-β receptor expression after 24 h (p
endoglin 
≤ 0.027). This 
suggests that TGF-β2 impacts TGF-β signaling in HSCs in 
a different manner than TGF-β1. Although Smad1, 2 and 
3 phosphorylation efficiency was similar when comparing 
TGF-β1 and -β2 treatment for 1 or 24 hours, respectively 
(Supplementary Figure 1A), 24 h TGF-β2 pretreated LX-2 
cells were sensitized for subsequent cytokine induced 
Smad1 signaling (Supplementary Figure 1B), probably 
due to the receptor upregulation described above. We 
therefore concluded that besides affecting TGF-β receptor 
expression, TGF-β2 seems to impact especially pSmad1 
signaling. Distinct mechanisms and outcomes (e.g., target 
gene expression) now need to be delineated.
Expression of TGF-β isoforms in CCl4-induced 
liver damage 
After analyzing TGF-β1 and -β2 expression and 
secretion in hepatocytes and HSCs, we aimed to translate 
our findings into in vivo models of liver diseases. In a 
model of liver regeneration upon acute liver damage by 
CCl
4
, we showed similar dynamics of TGF-β2 and TGF-β1 
expression within 6 days by quantitative realtime (q)PCR. 
Expression of both isoforms peaked on day 2 after CCl
4 
administration. Remarkably, a similarly transient increase 
in collagen expression was noticed on day 2 (Figure 3A). 
Encouraged by the correlating behavior of both TGF-β 
isoforms, we extended this study to chronic liver damage 
induced by CCl
4
. Mice were treated either with one CCl
4
 
injection, with 3 CCl
4
 injections within one week or with 
chronic treatment twice per week for six weeks. Also in 
this experiment, CCl
4
 treatment significantly enhanced 
TGF-β1 and -β2 expression. The highest expression of 
both isoforms was observed after six weeks of chronic 
treatment (Figure 3B). Interestingly, expression of both 
isoforms and collagen positively correlated in individual 
mice after six weeks of CCl
4
 treatment (Pearson 
Correlation Analysis p < 0.05) (Figure 3C). 
TGF-β isoform expression in models of biliary-
derived liver disease
To confirm whether the correlating expression 
pattern of TGF-β1 and -β2 holds true for different 
etiologies of liver fibrosis, we also analyzed bile duct 
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ligated (BDL) mice as a model for biliary fibrosis. These 
animals also displayed an elevation of TGF-β1 and -β2 
expression within a time course of 14 days after BDL. 
However, while TGF-β2 was strongly induced after 
14 days (~155-fold as compared to 0 h), there was only a 
slight induction of TGF-β1 expression during this period 
(~4-fold as compared to 0h) (Figure 4A), indicating a 
specific and probably more prominent role of TGF-β2 in 
biliary fibrosis. Time-resolved Fluidigm gene expression 
analysis revealed parallel induction of TGF-β1, TGF-β2 
and different fibrosis markers (Acta2, Col1a1, Col4a3, 
Col8a1, Timp1) (Figure 4B), underlining the possible 
involvement of TGF-β2 in the fibrotic process.
As TGF-β2 displayed a stronger regulation in the 
biliary fibrosis model than TGF-β1, we investigated the 
expression dynamics of both isoforms in MDR2-KO 
mice, a genetic model for cholestasis-based CLD. Using 
Fluidigm qPCR, MDR2-KO mice showed consistent 
TGF-β2 upregulation from 3 to 15 months compared to wild 
type animals (Figure 5A, lower panel). Although TGF-β1 
expression was significantly upregulated at the age of 3 
(~2-fold) and 9 (~2.5-fold) months in MDR2-KO animals, 
upregulation of TGF-β1 was notably weaker than that of 
TGF-β2 (Figure 5A, upper panel). In detail the results were: 
after 3 months, TGF-β2 ~10-fold and TGF-β1 ~1.9-fold; 
after 6 months, TGF-β2 ~3-fold and TGF-β1 ~1.7-fold; after 
9 months, TGF-β2 ~10-fold and TGF-β1 ~2.4 fold; and after 
15 months, TGF-β2 ~3.5-fold and TGF-β1 ~1.3-fold. 
Expression of TGF-β1 and TGF-β2 in 
murine HCC 
In MDR2-KO mice, TGF-β2 was strongly 
upregulated in very early stage CLD (3 months) as well as 
in late stage CLD (15 months). Generally, it is described 
that MDR2-KO mice develop cancer after about one year 
[41]. Thus, we decided to further analyze different HCC 
mouse models representing late or end stage CLD for 
Figure 1: TGF-β1 and -β2 expression and secretion in (A, B) primary mouse hepatocytes after 24 and 48 hours on 
collagen monolayer (CM) or collagen sandwich (CS) and (C, D) in quiescent (2 days) and culture-activated (8 days) 
primary mouse HSCs. (A) Relative expression of TGF-β1 (upper panel) and TGF-β2 (lower) in hepatocytes was analyzed using 
qPCR. (B) Secretion of TGF-β1 and -β2 by hepatocytes was measured using Quantikine ELISA. Data represent the summary of 3 to 4 
independent experiments and error bars represent standard error. After 2 and 8 days, (C) TGF-β1 and -β2 expression was determined by 
qPCR in reference to 2 days cultured HSCs and (D) secretion of TGF-β1 and -β2 was measured by Luminex ELISA. (E) Total TGF-β1 
and -β2 content was determined in HSC lysates after 2 and 8 days and quantified with Quantikine ELISA. Data are presented as the mean 
of 3 independent experiments and error bars represent standard deviation. 
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TGF-β2 expression. In TGFα/cMyc mice, significantly 
upregulated TGF-β2 expression but no upregulation 
of TGF-β1 expression was observed in tumor tissue 
compared to normal tissue (paired samples) (Figure 5B). 
TGF-β2 was also upregulated in tumors of DEN-
challenged mice compared to untreated controls after 
9 and 12 months, but not in comparison to surrounding 
tissue (Figure 5C–5D). After 12 months, TGF-β1 mRNA 
was significantly increased in tumors of DEN-treated mice 
compared to corresponding controls (Figure 5C, left) and 
in comparison to surrounding tissue of the same animals 
(Figure 5D, left). 
Expression of TGF-β1 and TGF-β2 in human 
HCC cell lines
As it is most relevant to translate our findings 
from mouse models to human samples, TGF-β2 and 
TGF-β1 mRNA expression levels were investigated in 
7 different hepatocellular carcinoma cell lines and one 
hepatoblastoma cell line (HuH6) (Figure 6A). TGF-β2 
was expressed in FLC-4, Hep3B, HLF, HLE, and HuH7 
cells with decreasing extent in the respective order. 
HuH6, PLC, and HepG2 expressed very low amounts of 
TGF-β2. After 4 days of culture, secretion of TGF-β2 
was low in PLC, HLE, HepG2, and HuH6 cells, but 
was high and in a similar range as TGF-β1 in Hep3B, 
HuH7, HLF, and FLC-4 cells (Figure 6B). Interestingly, 
in Hep3B and HuH7 cells, TGF-β2 secretion even 
exceeded TGF-β1 secretion significantly (p
Hep3B 
≤ 6E–05; 
p
HuH7 
≤ 0.0024). Knockdown of TGF-β2 using a specific 
antisense oligonucleotide (AON) revealed significant 
downregulation of the cell number and the expression of 
the proliferation marker PCNA in HuH7 (Supplementary 
Figure 2). Whether this accounts for compensatory or 
tumorigenic proliferations needs to be studied in the 
future. Together, our data suggest that TGF-β2 plays 
a noteworthy role in the cytokine signaling of distinct 
Figure 2: TGF-β1, TGF-β2 and TGF-β-receptor mRNA expression and TGF-β isoform secretion in LX-2 cells. (A) 
TGF-β1 and -β2 gene expression after 2 and 4 days and (B) secretion after 4 days cell culture. (C) qPCR analysis of TGF-β receptor 
expression after stimulation with 10 ng/ml TGF-β1 or TGF-β2 recombinant protein. Levels of TGF-β receptors in unstimulated cells at the 
time points indicated served as references. 
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HCC cell lines, which might be independent and have a 
different outcome than that of TGF-β1.
TGF-β1 and TGF- β2 expression in cirrhotic and 
HCC patients
Taken together, the analysis of HCC cell lines 
revealed significant TGF-β2 expression and secretion of 
HCC cells and mouse data suggest significant upregulation 
of TGF-β2 within liver tumor tissue (and not only of 
TGF-β1). Based on that knowledge, we investigated the 
occurrence of TGF-β isoforms in human HCC patients. 
The Oncomine® database was searched in order to analyze 
TGF-β expression in different HCC patient cohorts. 4 of 
7 studies reported TGF-β2 upregulation, whereas only 
one described TGF-β2 downregulation. TGF-β2 was 
one of the top 5–10% upregulated genes, while detected 
downregulation was less prominent (within 25% of 
downregulated genes). In the same cohorts, TGF-β1 was 
reported to be upregulated in two studies (within 25% of the 
most upregulated genes) and downregulated in two other 
studies (within 25% of the top downregulated genes) (Table 
1 and Supplementary Figure 3A). Analyzing cirrhotic 
patient cohorts via Oncomine®, we detected a continuous 
increase of TGF-β1 in line with disease progression 
from healthy via cirrhosis to HCC. In contrast, TGF-β2 
expression was higher at the cirrhosis stage than in normal 
liver and even higher than in HCC (Table 2, Supplementary 
Figure 3B–3C), suggesting a different regulation 
mechanism of the two isoforms during disease progression 
(Supplementary Figure 3D). 
We then decided to take a closer look at six 
further HCC cohorts. First, we selected those cohorts 
that exhibited significant p-values (p < 0.05) regarding 
TGF-β1 and/or TGF-β2 regulation in the respective 
studies (896 patients in total, summaries in Tables 3, 4, 5). 
It is worth noting that the p-value for expression changes 
provided was neither significant for TGF-β1 in the 
Figure 3: TGF-β1, TGF-β2 and Collagen 1a1 expression in acute and chronic CCl4- induced liver damage. (A) Within 
six days, expression dynamics of TGF-β1 and –β2 and Collagen 1a1 in the CCl
4
 regeneration model (1 hit) were determined by qPCR 
in comparison to untreated controls (B) TGF-β1 and –β2 mRNA expression was assessed 24 h after 1 CCl
4
 injection, 3 injections within 
one week or two injections per week for six weeks as indicated. (C) TGF-β1 and –β2 expression were correlated with Col 1a1 expression 
in 7 individual mice with chronic liver damage (6 weeks treatment). Pearson coefficients were r
TGF-β1/TGF-β2 
= 0.891, r
TGF-β1/Col1A 
= 0.723, 
r
TGF-β2/Col1A 
= 0.701, respectively.
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GSE5975 EpCAM positive and the GSE14520 cohorts, 
nor for TGF-β2 in the GSE4024/GSE1898 and GSE14520 
cohorts. Thus, they were excluded from this analysis. 
We then applied the selection criteria < −0.5 and > 0.5 
Log2 (fold change) to the analysis of individual patients´ 
expression data (single dots). Summarizing the results, 
TGF-β1 and -β2 were mainly upregulated compared to 
normal liver; however, a downregulation of TGF-β2 was 
obvious compared to surrounding tissue of the tumors 
(Figure 7). This implies that tumor-surrounding tissue 
itself is significantly altered as compared to normal liver 
and already displays changed TGF-β signaling signatures. 
Due to these and other specific changes of the tumor 
environment, which are known to impact tumorigenesis, 
expression changes need to be carefully investigated 
dependent on the context. Interestingly, analyzing patients 
with defined TGF-β2 regulation in GSE1898/4024, we 
found a correlation between high TGF-β2 expression and 
a poorer survival rate (p < 0.01) (Supplementary Figure 4), 
but not with other clinicopathological parameters 
including AFP levels, tumor size, differentiation grade, 
cirrhosis, and hepatoblast vs. hepatocyte subtype (data 
not shown), further suggesting tumor-promoting effects 
of TGF-β2.
DISCUSSION
In liver disease, TGF-β1 is described as a key 
player in the activation of myofibroblasts [42], hepatocyte 
apoptosis, and proliferation control [43]. Over the decades, 
its involvement in different stages of CLD and cancer has 
been investigated and discussed on a broad basis, and a lot 
Figure 4: TGF-β1, TGF-β2 and fibrotic marker expression in the bile duct ligation (BDL) model for cholestasis and 
secondary biliary fibrosis. (A) TGF-β1 and TGF-β2 expression were determined within a time course of 14 days after bile duct ligation 
(BDL). Relative expression was normalized to expression of GAPDH and referred to the mean ∆Ct of all samples. (B) Fluidigm gene 
expression analysis of typical fibrotic markers displayed in a heatmap. The color represents the expression level of the gene. Red represents 
high expression, while blue represents low expression. *p < 0.01; **p < 0.005; ***p < 0.001. 
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of information has been gathered since then. However, the 
TGF-β family consists of three isoforms with overlapping, 
but not redundant functions [24].
We comparatively investigated TGF-β1 and -β2 
expression in liver cells and diseased livers in various 
stages of progression. Probably due to more sensitive 
detection methods, we found that just like TGF-β1, TGF-β2 
is expressed in and secreted by both, healthy and diseased 
hepatocytes and HSCs. This is in contrast to some basic 
results reported about 25 years ago, where weak TGF-β1 
expression was only found near central veins and TGF-β2 
was only expressed in bile duct epithelial cells [44, 45]. 
However, those studies performed in the 1990s focused on 
the differences in isoform expression between different liver 
cell types. This led to underestimation of low expression or 
low signals were not interpreted as significant in comparison 
to strong signals, e.g., in Kupffer and bile duct cells.
In various models of regeneration, acute and 
chronic liver disease presented here, we were able 
to confirm knowledge of the expression patterns of 
TGF-β1 in liver disease. Reported information available 
on TGF-β2 in CLD and HCC is less comprehensive 
so far; however, it implies that TGF-β2 also acts in 
a profibrogenic and tumorigenic manner in different 
organs, including the liver. Wang et al. [46] demonstrated 
that i.p. administration of TGF-β2 in conjunction with 
CTGF - but not by itself - induced fibrosis of almost all 
abdominal organs, including the liver. This effect was 
rather systemically than organ-specific, but multifocal 
fibrosis of the hepatic capsule plus multiple foci of mild 
parenchymal fibrosis were detected. Since then, the role 
of TGF-β2 in fibrogenic mechanisms could be related 
to a variety of signaling mechanisms, which are partly 
based on canonical Smad2/3 signaling. In patients with 
chronic Hepatitis C and advanced fibrosis, upregulation 
of TGF-β2 correlated well with Smad2 expression 
[47]. Another indication of canonical TGF-β2 signaling 
was provided by Wang et al. [48], when they observed 
diminished TGF-β2 expression and subsequent Smad3 
activity upon miR-200a treatment in renal fibrogenesis.
Figure 5: Expression levels of TGF-β1 and TGF-β2 in murine CLD and HCC models. (A) TGF-β1 (upper panel) and -β2 
(lower panel) mRNA expression was examined in MDR2-KO mouse livers after 3, 6, 9, and 15 months and referred to wild type livers of 
animals at the same age. (B) Paired samples of TGFα/cMyc mice were analyzed by qPCR for TGF-β1 and -β2 expression. (C, D) In DEN-
induced HCC tumor samples from mice, TGF-β1 and –β2 expression was determined and compared to the respective PBS treated controls 
or surrounding tissue of the same animals. 
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However, non-canonical signaling and crosstalk of 
TGF-β2 have also been reported by different groups. A 
Wnt-TGF-β2 axis was discovered in muscle stem cells 
[49] and a study performed by Sun et al. [50] revealed 
TGF-β2 and β-Catenin as the two main functional targets 
of miR-200a expression in hepatic fibrosis. Further, Dong 
et al. uncovered a universal organ size control mechanism 
in metazoan, showing that Yap overexpression in the liver 
increased liver mass in transgenic mice extensively and 
strongly induced TGF-β2 expression [51, 52]. Together, 
these findings indicate possible mechanistic links for 
TGF-β2 and provide rationales for investigating these 
pathways in liver disease of different origins.
Although our data do not provide experimental 
evidence for mechanistic details so far, we have shown 
that in liver regeneration processes in which proliferation 
and apoptosis events need to be tightly controlled, TGF-β2 
is upregulated. During regeneration, expression of both 
isoforms of TGF-β peaked after day 2, coincident with 
collagen expression. For TGF-β1, this has been known for 
a long time; however, our data imply a similar importance 
of TGF-β2 in these regenerative processes. After repeated 
chemical intoxication, both TGF-β isoforms were further 
elevated simultaneously, suggesting a parallel and maybe 
synergistic function of the two isoforms in CCl
4
-induced 
progression of liver damage. 
In contrast to this concordant behavior in CCl
4
 
intoxication related liver disease, TGF-β2 expression 
patterns differed from those of TGF-β1 in biliary-derived 
models of liver damage. Interestingly, TGF-β2 was more 
significantly elevated in mice with bile duct ligation and 
at different time points of liver disease progression in 
MDR2-KO mice. This suggests a specific role of TGF-β2 
in the development of biliary-derived liver damage, 
which was already implicated in early results obtained by 
Milani et al., who described more prominent expression 
of TGF-β2 than TGF-β1 in bile duct epithelial cells, and 
particularly high TGF-β2 levels in proliferating bile ducts 
of fibrotic livers [53]. While a small study including 
eight twins (E-MTAB-2347) did not reveal TGF-β2 
deregulation in primary biliary cirrhosis (PBC), Shakel 
et al. [54] reported on upregulation of TGF-β2 in PBC, 
thus providing a further link between TGF-β2 and biliary-
derived liver diseases.
In a study including 87 ICC patients, TGF-β2 
expression was linked to bad survival and its 
overexpression in the ICC stroma was significantly 
associated with ICC classification, microvascular invasion, 
and the presence of hilar lymph nodes [33], indicating 
TGF-β2 as a possible prognostic marker for the clinical 
outcome of ICC and HCC. Recently, a brief report by 
Fan et al. [55] elegantly used fate tracing experiments to 
show that cholangiocarcinoma not only originates from 
biliary cells, but might also develop from a hepatocellular 
source. These data and our findings demonstrating TGF-β2 
expression in diseased liver cells, total liver and HCC 
lysates and its possibly special role in biliary diseases 
suggest studying the role of TGF-β2 in hepatocyte-derived 
cholangiocarcinomas in the future.
In the past, different HCC cell lines where 
thoroughly investigated regarding the expression of 
TGF-β1 [39, 56]. We were now able to show that almost 
all cell lines with high TGF-β1 mRNA expression also 
express high levels of the TGF-β2 isoform (r = 0.811; 
p = 0.015, data not shown). Most remarkably, two cell 
lines (Hep3B and HuH7) secreted even more TGF-β2 than 
TGF-β1, suggesting that tumorigenic signaling alteration 
in these cells is significantly affected by TGF-β2 signaling. 
Tschaharganeh et al. for example report that TGF-β2 
expression is specifically downregulated in YAP-deficient 
HuH7 cells [51].
In other cancer entities, further TGF-β2 dependent 
tumorigenic mechanisms have been discovered that 
might also play a role in liver cancer. Thus, TGF-β2 was 
able to drive tumor cell dormancy in a head and neck 
squamous cell carcinoma model in cooperation with 
Figure 6: TGF-β1 and TGF-β2 expression pattern in HCC cell lines. (A) Analysis of TGF-β1 and TGF-β2 expression by qPCR 
in 7 HCC cell lines and one hepatoblastoma cell line as indicated (B) After 4 days in culture, TGF-β isoform secretion was determined 
performing ELISA. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Table 1: HCC sample cohorts used for Oncomine® Research Edition based analysis of TGF-β1 and 
TGF-β2 expression
TGF-β2 Publication Samples
Measured 
Genes 
Total
Overexpression Underexpression
TGF-β2 
Gene 
Rank
Fold 
Change 
(Median 
Centered 
Ratio)
p-Value
TGF-β2 
Gene 
Rank
Fold 
Change 
(Median 
Centered 
Ratio)
p-Value
1
Chen Liver. 
Mol Biol 
Cell. 2002 
[76]
197 10.802 5239 (in top 49%) 1.107 0.221
2569 
(in top 
24%)
–1.258 0.006
2
Guichard 
Liver. Nat 
Genet. 2012 
[77]
185 18.823 838 (in top 5%) 1.114 1.08E–14
17148 
(in top 
92%)
1.114 1.000
3
Guichard 
Liver 2. Nat 
Genet. 2012 
[77]
52 18.823 787 (in top 5%) 1.103 4.32E–6
17195 
(in top 
92%)
1.103 1.000
4
Mas Liver. 
Mol Med. 
2008 [78]
115 12.603 890 (in top 8%) 1.191 1.56E–6
3547 
(in top 
29%)
–1.076 0.003
5
Roessler 
Liver. Cancer 
Res. 2010 
[79]
43 12.603 4250 (in top 34%) 1.194 0.046
5540 
(in top 
44%)
–1.029 0.118
6
Roessler Liv-
er 2. Cancer 
Res. 2010 
[79]
445 12.624 5015 (in top 40%) 1.053 0.001
5115 
(in top 
41%)
–1.034 0.004
7
TCGA Liver. 
No Associ-
ated Paper. 
2012
212 18.823 792 (in top 5%) 1.233 3.40E–15 ND ND ND
TGF-β1 Publication Samples
Measured 
Genes 
Total
TGF-β1 
Gene 
Rank
Fold 
Change 
(Median 
Centered 
Ratio)
p-Value
TGF-β1 
Gene 
Rank
Fold 
Change 
(Median 
Centered 
Ratio)
p-Value
1
Chen Liver. 
Mol Biol 
Cell. 2002 
[76]
197 10.802 10452 (in top 97%) –1.557 1.000
512 (in 
top 5%) –1.557 1.56E–12
2
Guichard 
Liver. Nat 
Genet. 2012 
[77]
185 18.823 5712 (in top 31%) 1.013 0.060
12282 
(in top 
66%)
1.013 0.940
3
Guichard 
Liver 2. Nat 
Genet. 2012 
[77]
52 18.823 ND ND ND
11608 
(in top 
62%)
1.007 0.820
4
Mas Liver. 
Mol Med. 
2008 [78]
115 12.603 1784 (in top 15%) 1.513 1.40E–4 X X X
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TGFβR-I, TGFβR-III and p38α/β. Accordingly, in lymph 
node metastatic cells, pp38, pSmad2 and pSmad1/5 were 
activated, while CDK4 was reduced by TGF-β2. This 
was in contrast to the effects of TGF-β1, arguing for 
independent actions of the two isoforms [57].
This is in line with our Oncomine®-based HCC 
cohort analysis, showing TGF-β2 upregulation in HCC 
as compared to normal liver, unlike TGF-β1, which was 
either not regulated or downregulated. Furthermore, this 
assumption is also valid for our in vivo mouse models of 
HCC. While TGF-β1 was significantly altered in tumors 
compared to surrounding tissue in DEN-induced HCC, 
TGF-β2 expression was significantly affected in tumors 
of TGFα/cMyc mice and DEN-treated mice compared to 
healthy liver. These data imply etiology specific-regulation 
of TGF-β2 in liver disease and the importance of the 
tumor environment. Differential expression of signaling 
components in normal liver vs. tumor surrounding tissue 
and vs. tumor tissue has to be analyzed carefully, as tumor-
surrounding tissue in the liver can hardly be considered 
to be healthy and is known to impact tumorigenesis on 
its own. Consequently, expression changes in the tumor 
as well as in the surrounding tissue do impact patient 
survival, while the ratio of the two expression levels does 
not necessarily reveal survival-relevant information [58]. 
One further step of complexity is provided to TGF-β 
isoform specific disease mechanisms by results showing 
an interdependence of the signaling of the different 
TGF-β isoforms. In the human cancer cell lines, DU145 
(human prostate adenocarcinoma) and A375 (human skin 
melanoma), Oh and colleagues [59] demonstrated that 
suppression of TGF-β1 induced TGF-β3 upregulation and 
therefore they may compensate each other for some, thus 
far unknown functions. Suppression of TGF-β2 induced 
5
Roessler 
Liver. Cancer 
Res. 2010 
[79]
43 12.603 1836 (in top 15%) 2.225 3.09E–4
5267 
(in top 
42%)
–1.071 0.093
6
Roessler Liv-
er 2. Cancer 
Res. 2010 
[79]
445 12.624 5677 (in top 45%) 1.098 0.043
3088 
(in top 
25%)
–1.111 3.69E–7
7
TCGA Liver. 
No Associ-
ated Paper. 
2012
212 18.823 5854 (in top 32%) 1.027 0.021
12130 
(in top 
65%)
1.027 0.979
Total number of samples, number of genes measured, p-values, gene ranks, and the fold change are given for TGF-β1 and 
TGF-β2 as indicated. Additionally, the table summarizes in which range of differentially expressed genes the respective gene 
was found in the study (top %). ND = not detected in the study.
Table 2: Liver cancer precursor and cirrhosis cohorts used for Oncomine® Research Edition based 
analysis of TGF-β1 and TGF-β2 expression
No. of cohort in Supplementary 
Figure 3 B + C Publication Reference Tissue
8 Mas Liver, Mol Med. 2008 [78] Cirhosis vs. normal
9 Wurmbach Liver, Hepatology 2007 [80] Cirhosis vs. normal
10 Wurmbach Liver, Hepatology 2007 [80] Dysplasia vs. normal
11 Chiang Liver 2, Cancer Res.2008 [81] HCC vs. Liver Cancer Type: Liver Cancer Precursor
12 Mas Liver, Mol Med. 2008 [78] HCC vs. Liver Cancer Type: Liver Cancer Precursor
13 Archer Liver, Cancer Epidemiol Biomarkers Prev. 2009 [82]
HCC vs. Liver Cancer Type: Liver 
Cancer Precursor
14 Chen Liver. Mol Biol Cell. 2002 [76] HCC vs. Liver Cancer Type: Liver Cancer Precursor
Number of the respective cohorts in Supplementary Figure 3B and 3C as well as the respective publications and reference 
tissues are given.
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downregulation of both, TGF-β1 and TGF-β3 and raises 
the assumption of a common transcription factor regulated 
by TGF-β2. Studies by Hellerbrand underlined the fact 
that the TGF-β2 and -β3 isoforms do not compensate the 
lack of TGF-β1 in the context of HSC activation in vivo, 
although HSCs were activated, suggesting participation of 
the other TGF-β isoforms [60]. Not only specific isoform 
depletion affected TGF-β isoform expression, also TGF-β1 
treatment could induce the expression of TGF-β2 via Rho 
kinase signaling as shown in data from Shimada et al. [36].
In summary, we directly compared the expression 
dynamics of TGF-β1 and TGF-β2 in the progression of 
liver disease of different etiologies for the first time in cell 
lines, animal models, and human patients. Our data suggest 
Table 3: HCC sample cohorts used for analysis of TGF-β1 and TGF-β2 expression
Publication
Array
Name
N°HCC 
Patients HCC Etiologies
Normal 
Liver
Surrounding 
Tissue
Roessler S. Cancer Res. 
2010  [79] GSE14520 247 HBV  247
Wang XW. Clin Cancer 
Res., 2007 [83] GSE5975 236 Ep_CAM +/−; HBV+; Cirrhosis +/-  236
Thorgeirsson S. Nature 
Genetics 2004 [84] GSE1898 91
HBV+; HCV+; co-infection; HBV/
Alcohol; HCV/Alcohol, Hemochro-
matosis
 91
Neumann O. Hepatology 
2012 [85] GSE50579 40
HBV+; HCV+; co-infection; Alco-
hol; Cryptogenic; Hemochromato-
sis; Others
7  
Shimokawa K. BMC 
Genomics. 2010 [86] iCOD 140
HBV+; HCV+; co-infection; Alco-
hol; HCV+ Alcohol, Diabetes; Cir-
rhosis; Unknown
NA  
Thorgeirsson S. Nature 
Genetics 2004 [84]
Lee JS et al. Nat Med 2006 
[87]
GSE4024/ 
GSE1898 142
HBV+; HCV+; co-infection; Alco-
hol; Cryptogenic; Hemochromato-
sis; ALD; NASH; Adenoma;  
Autoimmune; Unknown; Others
10
NA= not announced in the study.
Figure 7: Patient-resolved expression of TGF-β1 and TGF-β2 in different human HCC collectives. Free accessible 
databases (see Table 3) were used to investigate TGF-β1 and TGF-β2 expression in human HCC cohorts. Cohorts with significant p-values 
for TGF-β1 and/or TGF-β2 regulation were taken for further analysis (see Table 4). In individual patients (see single dots) 
expression changes of TGF-β1 and TGF-β2 were considered to be significant if the fold change (Log2) was ≥ 0.5 or ≤ −0.5. 
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Table 4: Significance of TGF-β1 and TGF-β2 expression changes in different HCC sample cohorts
TGF-β1 N°HCC Patients adj. p-value Mean Log2 (Fold Change)
GSE1898 91 2,53651E–07 0,47
GSE5975 EpCAM negative 142 0,00090135 −0,34
GSE5975 EpCAM positive 94 (0,36864697) −0,08
iCOD 140 NA −0,72
GSE50579 40 0,008 1,13
GSE4024/GSE1898 142 0,05 0,67
GSE14520 247 (0,35) 0,04
TGF-β2 N° HCC Patients adj. p-value Mean Log2 (Fold Change)
GSE1898 91 1,01742E–07 0,25
GSE5975 EpCAM negative 142 6,0118E–21 −0,57
GSE5975 EpCAM positive 94 2,25993E-09 −0,36
iCOD 140 NA 0,74
GSE50579 40 0,0001 1,42
GSE4024/GSE1898 142 (0,83) −0,03
GSE14520 247 (0,36) 0,01
Number of patients, p-values and fold change of TGF-β1 and TGF-β2 expression in the respective patient cohorts are listed. 
Only those cohorts with significant p-values were used for further analysis (See Figure 7). Non-significant p-values are given 
in brackets. NA = Not announced.
Table 5: Detailed analysis of HCC patient cohorts given in table 3 in regard to TGF-β1 and TGF-β2 up- and 
down-regulation
TGF-β1 N°patients Up-Reg.
N°patients 
Down-Reg.
% patients 
Up
% patients 
Down
%patients 
not Sig-
nificant
Mean 
Log2, Fold 
Change Up
Mean Log2, 
Fold Change 
Down
GSE1898 41 7 45,05 7,69 47,25 1,16 −0,66
GSE5975 EpCAM negative 65 33 45,77 23,24 30,99 1,26 −1,34
iCOD 16 26 11,43 18,57 70 1,45 −1,04
GSE50579 26 5 65 12,5 22,5 1,69 −1,78
GSE4024/GSE1898 61 10 42,96 7,04 50 1,02 −0,71
TGF-β2 N°patients Up-Reg.
N°patients 
Down-Reg.
% patients 
Up
% patients 
Down
%patients 
not Sig-
nificant
Mean 
Log2, Fold 
Change Up
Mean Log2, 
Fold Change 
Down
GSE1898 23 1 25,27 1,1 73,63 0,79 −0,60
GSE5975 EpCAM negative 7 83 4,93 58,45 63,38 0,91 −0,95
GSE5975 EpCAM positive 7 36 7,45 38,3 54,26 0,68 −0,86
iCOD 27 9 19,29 6,43 74,29 1,38 −1,16
GSE50579 29 4 72,5 10 17,5 1,76 −1,01
Only those cohorts with significant p-values for the respective genes are used for this analysis, thus excluding TGF-β1 
regulation in the GSE5975 EpCAM positive and GSE 14520 cohort as well as TGF-β2 in the GSE4024/GSE1898 and GSE 
14520 cohort (see Table 4).
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that distinct and independent as well as parallel roles exist 
for the two TGF-β isoforms in liver regeneration and the 
development of CLD. The significance and the mechanistic 
details of TGF-β2 regulation and effects are possibly 
etiology-dependent and have to be delineated. Specific 
multivariate analyses need to be performed and evaluated 
in order to make TGF-β2 a promising new candidate and 
target for the development of liver therapeutics.
MATERIALS AND METHODS
Ethics statement
This investigation has been conducted in 
accordance with ethical standards, the Declaration of 
Helsinki, and according to national and international 
guidelines, and has been approved by the authors’ 
institutional review board.
Cell culture
Human hepatocellular cancer cell lines -HepG2, 
Hep3B, PLC/PRF, HLE, HLF, FLC-4, and HuH7-, 
and the human HSC cell line Lieming Xu (LX)-2 [40] 
were cultured in Dulbecco’s modified Eagle’s medium 
(Lonza, Basel) with 10% fetal bovine serum for HCC 
cell lines, respectively 2% for LX-2 cells, 1% penicillin 
(100 IU/ml)/streptomycin (100 μg/ml), and 2 mM 
glutamine. Human hepatoblastoma cell line HuH6 cells 
were cultured in RPMI 1640 medium (Lonza, Basel) with 
10% fetal bovine serum, 1% P/S and 1% glutamine. The 
cells were maintained in a 37°C humidified atmosphere 
containing 5% CO
2
. 
24 hours prior to the HCC cell line and the HSC line 
experiments, medium was changed to ‘starvation medium’ 
with 0.5% FBS. 10 ng/ml TGF-β (PeproTech GmbH, 
Hamburg, Germany) were used for treatment. 
FLC-4 is a derivative cell line of JHH-4, and 
was obtained by starvation mutation from JHH-4 [61]. 
Detailed cell line information about JHH-4 can be 
obtained at http://cellbank.nibio.go.jp/~cellbank/en/
search_res_det.cgi?ID=1365.
Isolation and culturing of primary murine 
hepatocytes
Primary hepatocytes were isolated from livers of male 
C57BL/6 wild type mice by collagenase perfusion [62]. The 
cells were plated on collagen-coated plates and cultured in 
Williams E medium supplemented with with 10% fetal 
bovine serum, 1% penicillin (100 IU/ml)/streptomycin 
(100 μg/ml), 2 mM glutamine and 0,1% Dexamethasone. 
After 4 hours of attachment, the cells were overlayed with 
Williams medium for monolayer or with collagen and 
medium for sandwich culture. Collagen sandwich culture 
was performed as previously described [37].
Isolation of primary mouse HSCs
Primary HSCs were isolated from female BALB/c 
wild type mice by pronase/collagenase digestion followed 
by density gradient centrifugation and were cultured 
on plastic dishes in DMEM, supplemented with 4 mM 
L-glutamine, 10% FBS, and penicillin (100 IU/ml)/
streptomycin (100 μg/ml) as described in [63].
Reagents
All general chemicals were purchased from Carl 
Roth GmbH, Karlsruhe or from Sigma-Aldrich Co., USA, 
unless otherwise stated, and were of the highest quality. 
Animal models 
CCl4-induced liver injury
Acute liver injury was induced in 8-weeks 
old C57BL/6 mice (4 animals per group) through 
intraperitoneal injection of 1 ml/kg body weight 
CCl
4
 (mixed 1:8 with mineral oil), and the mice were 
sacrificed at 0 h, 3 h, 6 h, day 1, day 2, day 3, or day 6 
post injection [64]. For chronic liver injury, C57BL/6 or 
BALB/c mice received i.p. injections of CCl
4
 (0.7 ml/kg 
body weight in mineral oil) twice a week for six weeks 
(nut = 12; n24h = 12; n3x = 13; n6wk = 12 animals per group). 
The animals were sacrificed at indicated time points and 
the liver samples were immediately snap-frozen in liquid 
nitrogen. Specimen sampling was performed for RNA, 
protein, serum, and immunohistochemical analyses. 
Bile duct ligation (BDL) – induced cholestatic 
liver injury
The surgical procedure was carried out as previously 
described by Abshagen et al. [65, 66]. Under isoflurane 
anesthesia (1.5 vol%) male BALB/c mice (n = 3–5) were 
placed on a heat pad and laparatomized. The common bile 
duct was isolated, ligated three times with non-resorbable 
sutures (polyester 5–0; Catgut, Markneukirchen, Germany), 
and cut between the two gut-near ligatures. Sham-operated 
mice underwent a laparotomy with exposure but not ligation 
of the bile duct (0 h). The abdominal muscle and skin layers 
were stitched and the mice were treated with metamizole 
as an analgesic in their drinking water. The animals were 
allowed to recover from anesthesia and surgery under a red 
warming lamp and were held in single cages. After 0, 6, 
12, 18, or 30 hours or 2, 5, or 14 days mice were killed to 
obtain blood and liver samples (n =3–5). 
MDR2-KO model
Mdr2−/− mice (MDR2-KO) and control wild 
type animals were maintained in a specific pathogen-
free environment and the experiments were performed 
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with age-matched male mice. Genotyping was done as 
described elsewhere [67], and liver and blood samples 
were obtained at the corresponding time points as 
described previously [68]. 
DEN model - chemical-induced liver carcinogenesis
Male mice at 15 days of age received intraperitoneal 
injections of DEN (5 mg/kg) diluted in saline buffer; 
the control animals were injected with saline buffer 
intraperitoneally. At the indicated time points, the mice 
were sacrificed and their livers removed. Total RNA was 
isolated from frozen tissues to analyze gene expression 
by real-time quantitative PCR. Three to four animals per 
condition and two different tissue pieces per animal were 
processed for RNA extraction [69].
TGFα/cMyc transgenic mouse model for 
hepatocarcinogenesis 
Double transgenic TGFα/cMyc mice were generated 
by crossing c-Myc mice with TGF-α mice as described in 
[70]. In male TGFα/cMyc mice, hepatocarcinogenesis was 
triggered by the addition of ZnCl
2
 to the drinking water. 
Tumor development in the liver was detected by Gd-EOB-
DTPA-enhanced magnetic resonance imaging [71]. Tumor 
and normal liver tissue were dissected and frozen at −80°C 
until use.
RNA isolation and cDNA synthesis
Total RNA was extracted according to the 
manufacturer’s instructions using either peqGOLD 
RNAPure (Peqlab Biotechnologie, Erlangen, Germany) 
or with Trizol reagent (Life Technologies) and were 
purified via chloroform extraction or using the High 
Pure RNA Isolation Kit (Roche). The RNA concentration 
was determined with the help of the Tecan infinite M200 
Microplate reader (Tecan, Switzerland). Subsequently, 
cDNA was synthesized from 0.5–1 μg RNA with the 
Transcriptor First Strand cDNA Synthesis Kit (Roche).
Quantitative real-time PCR
Real-time polymerase chain reaction (qPCR) was 
carried out with Power SYBR Green (Life Technologies) 
or TaqMan Universal Master Mix II (Life Technologies) 
using the Stratagene MX 3005 P system. The primers 
and probes are listed in supplementary Tables 1 and 2, 
respectively. To ensure that the primers produced specific 
PCR amplification products, a dissociation curve was 
analyzed to guarantee specificity. (Only primers with a 
unique dissociation peak were selected). To compensate 
for the variation between qPCR runs, the target gene 
expression was normalized to the expression of the 
endogenous, unregulated reference gene rS18 or PPIA. 
The relative quantity of target genes was determined 
according to the ΔΔCt (“delta-delta”) method [72].
High-throughput gene expression analysis using 
microfluidic fluidigm’s biomark HD quantitative 
chip platform 
For high-throughput quantitative Taqman qPCR 
analysis, we used the microfluidic Fluidigm’s BioMark 
HD high-throughput quantitative chip platform (Fluidigm 
Corporation, San Francisco, CA, USA) with pre-designed 
gene expression assays from Life Technologies according 
to the manufacturer’s instructions [73] and as previously 
described [74]. The data were analyzed using the ΔΔCt 
method [75] and the expression values were normalized to 
the expression levels of the housekeeping genes (β-actin, 
tubulin, GAPDH). 
TGF-β2 inhibition using antisense 
oligonucleotides (AONs)
HuH7 cells were cultured at medium density 
to perform AON experiments. TGF-β2 inhibition 
oligonucleotides were provided by Isarna Therapeutics. 
AON or scrambled oligonucleotide transfection was 
performed using RNAiMAX (Invitrogen, Darmstadt, 
Germany) according to the manufacturer’s protocol. 
Knockdown efficiency was verified by qPCR. The final 
AON and scrambled control concentration was 20 nmol. 
Knockdown was allowed to establish for 48h in medium 
supplemented with 2% FBS.
ELISA 
Enzyme-linked immunosorbent assays (ELISAs) 
were performed to estimate the levels of secreted TGF-β1 
and TGF-β2 in cell supernatants after normal cell culture. 
For lysates, the cell culture medium was removed by 
centrifugation, Cell Lysis Buffer 1 (R & D Systems) 
was added to the cell pellet and the mixture was allowed 
to incubate for 60 minutes with gentle agitation. After 
activating TGF-β through acidification in the collected 
supernatants or lysates, ELISAs were performed according 
to the manufacturer’s instructions for Quantikine human 
TGF-β1 or murine TGF-β1 (R & D Systems, Minneapolis, 
USA) or Quantikine human TGF-β2 or murine TGF-β2 
(R & D Systems, Minneapolis, USA), respectively. For 
measuring TGF-β1 and TGF-β2 secretion of murine 
HSCs, an ELISA-based system, Luminex, was purchased 
from BioRad. 
Immunoblot
Proteins were separated by SDS-PAGE, and then 
electrically transferred onto a nitrocellulose membrane. 
Primary antibodies against pSmad2, Smad1, Smad2/3 
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(Cell Signaling Technology), pSmad1/3 (Abcam), 
and GAPDH (Santa Cruz) were used according to the 
manufacturer’s recommendations. HRP-conjugated 
secondary antibodies were goat anti-rabbit IgG-HRP or 
goat anti-mouse IgG-HRP (Santa Cruz). Protein detection 
was performed using the Super Signal West Dura 
Extended Duration Substrate (Thermo Scientific). All 
experiments were performed multiple times.
Statistical analysis
Error bars represent standard error to the mean. 
Deviations were used, unless described otherwise; 
two-tailed Student-t tests or one-way ANOVA were 
used to calculate the p-values. Additionally, Pearson 
correlation was performed. Differences were considered 
to be significant if the calculated p-value was *p < 0.05, 
**p < 0.01, ***p < 0.001; the p-values were not significant 
if not indicated.
Patient collectives
Publicly available databases (iCOD omics.tmd.
ac.jp/icod_pub_eng/; Oncomine https://www.oncomine.
org/; GEO, http://www.ncbi.nlm.nih.gov/gds; and 
Arrayexpress, http://www.ebi.ac.uk/arrayexpress/), as 
well as data generated within the former SFB/TRR77 on 
Liver Cancer (GSE50579; GEO ID) and those collected 
from our own collaborative projects, were used in order 
to analyze expression of TGF-β1 and TGF-β2. The tools 
Bioconductor (R) 2.13 (3.0.1) and GraphPad Prism 6 
were used to retrieve and analyze data from six HCC 
sample cohorts (GSE5975, GSE1898, GSE50579, iCOD, 
GSE4024/GSE1898, GSE14520) comprising a total 
number of 896 HCC patients, presented from different 
etiologies. The expression values were matched to 
normal liver samples and/or to each patient´s surrounding 
non-cancer tissue. The following criteria were used at 
different stages of the screen: (1) significance below 0.05 
(p-value < 0.05), (2) number of cohorts with significant 
differences in the TGF-β1 and TGF-β2 expression 
(≥ 3), and (3) tendency of TGF-β1 and TGF-β2 expression 
within different cohorts (up- or down-regulated). The 
Oncomine® Research Edition was used to analyze 
7 additional HCC collectives and 7 cirrhosis/precancerous 
stage collectives for TGF-β1 and TGF-β2 expression (for 
more details, see Tables 1 and 2). As criteria for analysis 
of expression changes in HCC vs normal, in cirrhosis/
precancerous stages vs normal, and in HCC vs cirrhosis/
precancerous stages p-values of < 0.05 were set.
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TGF-β - Transforming growth factor, TGF-βR-I, 
II, III - Transforming growth factor receptor type I, 
II and III, CM - collagen monolayer, CLD - chronic 
liver disease, Col1a1 – Collagen 1a1, CS - collagen 
sandwich, ELISA – enzyme–linked immunosorbent 
assay, HCC - hepatocellular carcinoma, HSC - hepatic 
stellate cell, CCL
4 
– carbontetrachloride, BDL - bile duct 
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cholangiocarcinoma, DMEM - Dulbeccoʼs Modified Eagle 
Medium, KO - knock out, MDR2 – multi drug resistance 
protein 2, phosphatidyl flippase, qPCR - quantitative 
realtime polymerase chain reaction, SYBR - N′,N′-
dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-ylidene)
methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-
1,3-diamine, LX-2 – human hepatic stellate cell line 
Lieming Xu-2, HepG2, Hep3B, PLC/PRF, HLE, HLF, 
FLC-4, HuH7 - human hepatocellular carcinoma cell 
lines, HuH6 – human hepatoblastoma cell line, C57BL/6, 
BALB/c – wild type mouse strains.
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